Mitobridge
Cambridge, Massachusetts, United States
About Mitobridge
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions. Building upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies, the Company is progressing innovative approaches to the treatment of diseases with a high unmet medical need. Their strategy is to establish proof of concept in rare diseases and then expand into more common diseases. Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Their scientific founders and advisors include leaders in mitochondrial biology, metabolism, and aging with experience in translating novel discoveries into next-generation medicines. The Company was founded in October of 2013 with financing from MPM Capital, Longwood Fund, and Astellas Pharma and a shared vision for the promise of mitochondrial-targeted therapeutics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.2M
- Funding stage: M&A
- Last round: Series A (Oct 2013)
- Website: mitobridge.com
- Phone: (617)401-9100
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mitobridge-2247284 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.